Dry Age-Related Macular Degeneration (AMD) affects over 2 million Canadians and remains a leading cause of visual impairment in the aging population. Until recently, therapeutic options have been limited to nutritional supplementation and lifestyle modifications.

Join us to explore microcurrent stimulation, the first treatment to receive Health Canada-approval with a clinical indication to improve visual function in Dry AMD patients.

Gain interdisciplinary insights into the evolving landscape of Dry AMD management, and discover practical strategies for integrating this novel therapy into clinical practice.

This session will feature case studies, clinical cutcomes, and expert perspectives from an ophthalmologist and an optometrist

Breakfast provided and sponsored by: MacuMira Therapeutic Inc.